BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Study acronym: BLOOD-dose
StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases. The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions. New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.
Trial Details
NCT Number NCT07474961
Lead Sponsor Anne Louise Tølbøll Sørensen
Conditions
(from sponsor)		 Waldenstrom Macroglobulinaemia, Multiple Myeloma
Related terms Multiple Myeloma, Waldenstrom Macroglobulinemia
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov